CAS 66794-74-9|Encainide hydrochloride
Introduction：Basic information about CAS 66794-74-9|Encainide hydrochloride, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Encainide hydrochloride | ||
|---|---|---|---|
| CAS Number | 66794-74-9 | Molecular Weight | 388.93100 |
| Density | 1.106g/cm3 | Boiling Point | 439.9ºC at 760mmHg |
| Molecular Formula | C22H29ClN2O2 | Melting Point | / |
| MSDS | ChineseUSA | Flash Point | 219.8ºC |
| Symbol | GHS06 | Signal Word | Danger |
Names
| Name | encainide hydrochloride |
|---|---|
| Synonym | More Synonyms |
Encainide hydrochloride BiologicalActivity
| Description | Encainide (MJ9067) hydrochloride is an antiarrhythmic drug with class IC activity. Encainide has the potential for life-threatening ventricular arrhythmias, symptomatic ventricular arrhythmias and supraventricular arrhythmias research[1]. |
|---|---|
| Related Catalog | Research Areas >>Cardiovascular DiseaseSignaling Pathways >>Others >>Others |
| In Vivo | Encainide hydrochloride (MJ9067 hydrochloride; 0.3, 0.9, 2.7 mg/kg; infusion of single doses) prolongs His-Purkinje conduction time (HV interval) and intra-ventricular conduction time (QRS duration) but has no effect on sinus nodal recovery time or AV nodal conduction, or on refractoriness of atrium, AV node, or ventricular myocardium or on QT interval[1]. |
| References | [1]. R N Brogden, et al. Encainide. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1987 Nov;34(5):519-38. |
Chemical & Physical Properties
| Density | 1.106g/cm3 |
|---|---|
| Boiling Point | 439.9ºC at 760mmHg |
| Molecular Formula | C22H29ClN2O2 |
| Molecular Weight | 388.93100 |
| Flash Point | 219.8ºC |
| Exact Mass | 388.19200 |
| PSA | 41.57000 |
| LogP | 5.17730 |
| InChIKey | OJIIZIWOLTYOBS-UHFFFAOYSA-N |
| SMILES | COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1.Cl |
| Storage condition | 2-8°C |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 57 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 86 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 16 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 43 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 17 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Primate - monkey
- DOSE/DURATION :
- 8 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 5500 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
Safety Information
| Symbol | GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301-H315-H319-H335 |
| Precautionary Statements | P261-P301 + P310-P305 + P351 + P338 |
| Personal Protective Equipment | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
| Hazard Codes | T |
| Risk Phrases | 25-36/37/38 |
| Safety Phrases | 26-45 |
| RIDADR | UN 2811 6.1/PG 3 |
| RTECS | CV5521500 |
Articles26
More Articles| Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents. Clin. Pharm. 6(11) , 839-50, (1987) The chemistry, electrophysiology, pharmacokinetics, clinical use and efficacy, adverse effects, drug interactions, and dosage of encainide hydrochloride and flecainide acetate are reviewed. Encainide ... | |
| ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia. J. Cardiovasc. Electrophysiol. 9(11) , 1167-72, (1998) Three patients in whom Class IC sodium channel blockers induced ST segment elevation in leads V1 through V3 are described. The underlying electrophysiologic mechanism, implications for drug-induced pr... | |
| Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST). Ann. Epidemiol. 6(2) , 93-101, (1996) Patient adherence to therapy is essential to assess treatment efficacy, particularly in clinical trials. Active treatment usually is expected to benefit patients. The healthy adherer effect, the assoc... |
Synonyms
| (+-)-2'-(2-(1-Methyl-2-piperidyl)ethyl)-p-anisanilide monohydrochloride |
| 4-methoxy-N-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide,hydrochloride |
| Benzamide,4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-,monohydrochloride,(+-) |
| Encainide hydrochloride |
| 4-Methoxy-2'-(2-(1-methyl-2-piperidyl)ethyl)benzanilide hydrochloride |
| Encainide HCl |
| Encainide hydrochloride (USAN) |
| Enkaid |
